The Food and Drug Administration approved a higher-dose version of a popular class of obesity drugs on Thursday, the latest expansion in a rapidly growing market for weight-loss treatments.

The newly authorized dose of Novo Nordisk’s Wegovy increases the maximum weekly injection from 2.4 milligrams to 7.2 milligrams, offering patients a stronger option if they have not achieved the desired results with existing therapies.